Graft-Versus-Host Disease

The FDA approved ruxolitinib for treatment of certain patients with chronic graft-versus-host disease.

For years, hematopoietic stem cell transplantation physicians have viewed a matched unrelated donor as the gold standard when a matched related donor is unavailable.

The FDA granted priority review to abatacept for prevention of moderate to severe acute graft-versus-host disease among patients aged 6 years or older receiving unrelated donor hematopoietic stem cell transplantation.

Post-transplant cyclophosphamide reduced incidence of graft-versus-host disease but led to higher incidence of early cardiac events after allogeneic hematopoietic stem cell transplantation, according to study results.

The FDA today approved belumosudil for treatment of patients aged 12 years or older with chronic graft-versus-host disease, according to the agent’s manufacturer.

The FDA granted fast track designation to neihulizumab for treatment of steroid-refractory acute graft-versus-host disease according to the agent’s manufacturer.

The FDA granted priority review to ruxolitinib for the treatment of adults and children aged 12 years or older with steroid-refractory chronic graft-versus-host disease, according to a manufacturer-issued press release.

Ruxolitinib appeared more effective than best available therapy for steroid-refractory or steroid-dependent chronic graft-versus-host disease, according to randomized phase 3 study results presented at TCT Meetings Digital Experience.

The majority of patients with chronic graft-versus-host disease are unable to discontinue immunosuppressive therapy for more than 1 year, according to retrospective study results presented at TCT Meetings Digital Experience.

Patients with graft-versus-host disease who developed steroid-related complications required substantial health care resource utilization and incurred considerable costs, according to results presented at TCT Meetings Digital Experience.